Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients

Note: This trial closed to accrual on 12/15/04. Use of the lower-dose STS was discontinued on 05/31/05. Any patients joining the study after 05/31/05 assigned to the interventional arm or who are currently enrolled in Step 2 will receive the higher-dose STS. Inclusion Criteria: * HIV infected * Stable anti-HIV therapy or no anti-HIV therapy for at least 8 weeks prior to study screening * AIDS Dementia Complex Stage of greater than 0 * Decreased mental function as shown by tests during screening * IQ of 70 or greater * Willing to use acceptable methods of contraception during study and for 3 months following study Exclusion Criteria: * Tumor involving a large organ or requiring chemotherapy. Patients with basal cell carcinoma, in situ carcinoma of the cervix, or Kaposi's sarcoma are not excluded. * Serious mental illness that, in the opinion of the investigator, might interfere with the study * Reserpine or meperidine within 7 days prior to study entry * Nefazodone within 14 days prior to study entry * Monoamine oxidase inhibitor, including selegiline, within 30 days prior to study entry * Sympathomimetic medications, including over the counter diet and cold (oral or nasal) remedies, within 14 days of study entry * Decreased blood pressure when standing up * Uncontrolled high blood pressure * Active symptomatic AIDS-defining opportunistic infection within 30 days prior to study entry * Nervous system disorders such as multiple sclerosis, stroke, serious head injury, uncont…